Claims
- 1. A method of treating a cancer comprising administering a pharmaceutical composition to a mammal in need thereof, in a sufficient amount to suppress the initiation, promotion, or progression of the cancer, said composition comprising an active agent selected from the group consisting of brusatol, bruceantin, glancarubolone, and derivatives thereof.
- 2. The method of claim 1 wherein the composition is a solid.
- 3. The method of claim 1 wherein the composition is a liquid.
- 4. The method of claim 1 wherein the composition is administered orally.
- 5. The method of claim 1 wherein the composition is administered parenterally.
- 6. The method of claim 1 wherein the composition is administered prior to exposure of the mammal to a carcinogen or a procarcinogen.
- 7. The method of claim 1 wherein the composition is administered during or after exposure of the mammal to a carcinogen or a procarcinogen.
- 8. The method of claim 1 wherein the mammal is a human.
- 9. The method of claim 8 wherein the composition is administered in a sufficient amount to produce a suppressing effect on a cancer.
- 10. The method of claim 1 wherein the cancer is a hematologic malignancy.
- 11. The method of claim 10 wherein the cancer is a leukemia or a lymphoma.
- 12. The method of claim 1 wherein the leukemia or lymphoma is selected from the group consisting of acute myeloid leukemia, acute lymphoblastic leukemia, blast-phase chronic myeloid leukemia, Burkitt's leukemia, Burkitt-like leukemia, and high-risk myelodysplastic syndrome.
- 13. The method of claim 1 wherein the composition further comprises an excipient.
- 14. The method of claim 1 wherein the active agent is present in an amount of about 0.1% to about 75%, by weight of the composition.
- 15. The method of claim 1 wherein the active agent has an antiproliferative IC50 value versus HL-60 cells of about 2 μM or less.
- 16. The method of claim 1 wherein the active agent has a cytotoxicity IC50 value of 0.1 μM or greater.
- 17. The method of claim 1 wherein the active agent has a selectivity index of greater than 1.
- 18. The method of claim 1 wherein the active agent has a selectivity index of greater than 2.
- 19. The method of claim 1 wherein the active agent has a selectivity index of about 2.5 to about 7.
- 20. The method of claim 1 wherein the active agent is selected from the group consisting of
- 21. The method of claim 1 wherein the active agent is selected from the group consisting of
- 22. The method of claim 1 wherein the active agent is selected from the group consisting of
- 23. A method of treating a cancer comprising administering therapeutically effective amounts of an active ingredient to an individual in need thereof, to suppress the initiation, promotion, or progression of the cancer, said active agent capable of modulating c-Myk or related oncogenes or transcriptase factors.
- 24. The method of claim 23 wherein the cancer is hematologic malignancy.
- 25. The method of claim 24 wherein the cancer is a leukemia or a lymphoma.
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of U.S. provisional patent application Serial No. 60/266,543, filed Feb. 5, 2001.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60266543 |
Feb 2001 |
US |